Table 2. Clinical characteristics of 5-FU treated patients with and without TYMS amplification.

Patient group	TYMS status in metastasis	Previous treatment	Age, years	Stage at diagnosis	Metastasis size, cm	Metastasis location	Median survival after metastasis removal (survival range)
Group A (n = 6)	Amplified	5-FU	65	I-0%	2.2	Liver-67%	329 days (109-708 days)
				II-0%		Lung-0%
				III-33%		Brain-33%
				IV-50%
				ND-17%
Group B (n = 21)	Not amplified	5-FU	63	I-5%	3.2	Liver-80%	1,021 days (255-3,790 days)
				II-10%		Lung-10%
				III-29%		Brain-10%
				IV-43%
				ND-14%